Synthetic site-specific rna editing entities
AssigneeEnzerna Biosciences, Inc.
InventorsJoseph RUIZ, Zefeng WANG
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions comprising synthetic site-specific RNA editing entities engineered to target pathogenic RNA comprising a CAG repeat associated with a CAG repeat disorder. Also disclosed herein are methods of treating the CAG repeat disorders of the present disclosure, such as Huntington's disease with the compositions and pharmaceutical formulations comprising the compositions disclosed herein.
Claims21
-100. (canceled)
A synthetic RNA binding domain comprising an amino acid sequence with at least 90% sequence identity to SEQ ID NO:
- 6.
A synthetic RNA binding domain comprising an amino acid sequence with at least 95% sequence identity to SEQ ID NO:
- 10.
A synthetic site-specific RNA editing entity targeting a pathogenic RNA that comprises a CAG repeat, the synthetic site-specific RNA editing entity comprising:
- (i) a synthetic RNA binding domain;
- and (ii) a cleavage domain;
- wherein the synthetic RNA binding domain comprises an amino acid sequence comprising (Cys/Ser/Asn)XxxXxxXxxGln that binds to adenine, wherein Xxx is any amino acid.
Dependencies are inferred from the claim text.